Getting insurance to cover ketamine infusions is difficult but not always impossible, and the path you take depends largely on which form of ketamine you’re pursuing and why. The key distinction: Spravato (esketamine nasal spray) is FDA-approved for treatment-resistant depression, so major insurers often cover it with prior authorization. IV ketamine, the more common infusion form, is considered off-label for mental health and pain conditions, making direct insurance coverage rare. That said, there are several strategies that can improve your chances of getting at least partial reimbursement.
Why Spravato Is Easier to Get Covered
The single biggest factor in whether insurance will pay is FDA approval status. Spravato, a nasal spray containing the S-enantiomer of ketamine, has FDA approval specifically for treatment-resistant depression. That approval gives insurers a framework to authorize coverage. Major carriers including Blue Cross Blue Shield, Aetna, and UnitedHealthcare have pathways for covering Spravato when you meet their clinical criteria.
IV ketamine uses racemic ketamine, which is FDA-approved only as an anesthetic. When clinics administer it for depression, PTSD, or chronic pain, that’s considered off-label use. Insurance companies treat off-label use very differently, and most will not cover IV ketamine infusions directly. Aetna, for example, explicitly classifies intravenous ketamine as “experimental, investigational, or unproven” for CRPS, other chronic pain conditions, and depression.
If your primary goal is treating depression and you haven’t tried Spravato yet, pursuing that route first gives you the most realistic shot at insurance coverage. It also strengthens a future case for IV ketamine if Spravato doesn’t work for you.
Meeting Prior Authorization Requirements
Even for Spravato, insurers won’t simply approve coverage on request. You’ll need to go through prior authorization, which means your provider submits documentation proving you meet specific clinical criteria. Based on typical insurer requirements, here’s what you’ll need to demonstrate:
- A documented diagnosis of moderate to severe major depressive disorder (or another covered indication).
- Failed trials of other antidepressants. Most plans require that you’ve had an inadequate response to at least an 8-week trial at the maximum tolerated dose of three different classes of antidepressants. You need records showing which medications you tried, the dates of treatment, and why each one failed.
- Concurrent antidepressant use. Insurers typically require that you’re currently taking an antidepressant and will continue it alongside ketamine treatment.
- No recent substance abuse history. Plans will ask whether you have a recent history of substance or alcohol use disorder, which can complicate approval.
The most common reason prior authorization requests get dismissed is incomplete documentation. Every medication trial, every therapy attempt, every failed treatment needs to be in your chart notes with specific dates and reasons for discontinuation. Work with your prescribing provider to compile this history before submitting. If your treatment records are spread across multiple providers, gather them in advance so nothing is missing from the request.
For reauthorization after an initial approval period, you’ll need clinical documentation showing continued medical necessity and a positive response to treatment.
The Out-of-Network Reimbursement Route
If you’re pursuing IV ketamine infusions specifically, direct coverage is unlikely. But partial reimbursement through your out-of-network benefits is worth exploring. Here’s how it works in practice:
First, call your insurance company before starting treatment and ask specifically about out-of-network reimbursement for ketamine infusions. Ask what your out-of-network deductible is, what percentage they reimburse after the deductible is met, and whether they have any exclusions for ketamine. Some plans will reimburse a portion of out-of-network services even when they wouldn’t cover the same service in-network.
If your plan does offer out-of-network reimbursement, you’ll pay the clinic directly at the time of service, then submit a claim to your insurer afterward. The key document here is a superbill: an itemized form your ketamine provider prepares that lists the services you received, the diagnosis codes, the procedure codes, and the charges. You submit this superbill to your insurance company along with a claim form. Each insurer has its own process for handling these submissions, so get the specific instructions from your plan before your first appointment.
Not every ketamine clinic provides superbills, so ask about this before committing to a provider. A clinic experienced with insurance reimbursement will know how to code services in a way that gives your claim the best chance.
How Diagnosis Affects Your Options
Your diagnosis matters for coverage in ways that go beyond just qualifying for prior authorization. Depression, particularly treatment-resistant depression, has the clearest path to coverage because that’s the FDA-approved indication for Spravato. Medicare, for instance, has specific billing codes (G2082 and G2083) set up for esketamine administration at certified facilities.
Chronic pain conditions like CRPS present a harder case. Despite growing clinical use of ketamine for these conditions, major insurers have not broadly accepted the evidence. Aetna’s clinical policy bulletin lists IV ketamine for CRPS as experimental, and many other carriers follow similar positions. If you’re seeking ketamine for pain, you’re almost certainly looking at out-of-pocket costs with the possibility of partial out-of-network reimbursement.
For conditions like PTSD, anxiety, or bipolar depression, coverage is even less standardized. These are all off-label uses, and your success in getting any reimbursement will depend heavily on your specific plan and how your provider documents the medical necessity.
Choosing the Right Provider
Where you get treatment significantly affects your reimbursement odds. Spravato can only be administered at healthcare sites enrolled in the FDA’s Risk Evaluation and Mitigation Strategies (REMS) program, which is a safety monitoring requirement. If your provider isn’t REMS-certified, your Spravato claim will be denied regardless of your diagnosis or treatment history.
For IV ketamine, look for providers who operate within a medical practice rather than standalone wellness clinics. A psychiatrist or anesthesiologist who bills under standard medical codes and provides detailed clinical documentation will give you much stronger paperwork for insurance submissions than a clinic that operates on a cash-only model. Ask prospective providers whether they have experience working with insurance companies on ketamine claims, whether they provide superbills, and what diagnosis and procedure codes they use.
What to Do After a Denial
If your prior authorization or reimbursement claim is denied, you have the right to appeal. The appeal process typically involves submitting a letter from your provider explaining why ketamine is medically necessary for your specific case, along with supporting documentation of all treatments you’ve tried and failed. Peer-reviewed literature supporting ketamine for your condition can strengthen the appeal, and many providers who regularly prescribe ketamine will have template letters and citations ready for this purpose.
Most insurers have two levels of internal appeal before you can request an external review by an independent third party. The external review is often your best chance at overturning a denial, because the reviewer is not employed by the insurance company. Keep detailed records of every communication with your insurer, including dates, names of representatives, and reference numbers for each call.
Realistic Cost Expectations
If you end up paying out of pocket, IV ketamine infusions typically run $400 to $800 per session, with an initial series of six infusions over two to three weeks being standard. That puts the initial treatment cost between $2,400 and $4,800 before maintenance infusions, which are usually needed every few weeks to months. Spravato sessions generally cost $600 to $900 each before insurance, but with coverage, your out-of-pocket share may be limited to a copay.
Some clinics offer payment plans or sliding-scale pricing. The manufacturer of Spravato also offers a savings program that can reduce copays for commercially insured patients. If you have a health savings account (HSA) or flexible spending account (FSA), ketamine infusions prescribed by a licensed provider for a medical condition are generally eligible expenses, which at least gives you a tax advantage on out-of-pocket costs.